200 related articles for article (PubMed ID: 36301933)
41. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004
[TBL] [Abstract][Full Text] [Related]
42. Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting.
Lombardi F; Belmonti S; Moschese D; Fabbiani M; Borghetti A; Ciccullo A; Visconti E; Di Giambenedetto S
HIV Res Clin Pract; 2022 Dec; 23(1):28-36. PubMed ID: 35758043
[No Abstract] [Full Text] [Related]
43. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Acosta RK; Willkom M; Martin R; Chang S; Wei X; Garner W; Lutz J; Majeed S; SenGupta D; Martin H; Quirk E; White KL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803969
[TBL] [Abstract][Full Text] [Related]
44. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
45. Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Bendala-Estrada AD; Diaz-Almiron M; Busca C; Mican R; Cadiñanos J; Montes ML; Martin-Carbonero L; Valencia E; Montejano R; Delgado-Hierro A; Bernardino JI
HIV Med; 2023 May; 24(5):558-567. PubMed ID: 36394195
[TBL] [Abstract][Full Text] [Related]
46. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
47. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A
New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892
[TBL] [Abstract][Full Text] [Related]
48. A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.
Ferrer PE; Bloch M; Roth N; Finlayson R; Baker D; Koh K; Orth D; Urbaityte R; Brown D; Drummond F
Int J STD AIDS; 2018 Mar; 29(3):300-305. PubMed ID: 28901212
[TBL] [Abstract][Full Text] [Related]
49. Real world use of dolutegravir two drug regimens.
Bowman C; Ambrose A; Kanitkar T; Flores K; Simoes P; Hart J; Hunter A; Akodu J; Barber TJ
AIDS; 2023 Apr; 37(5):785-788. PubMed ID: 36728219
[TBL] [Abstract][Full Text] [Related]
50. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
51. HIV 101: fundamentals of antiretroviral therapy.
Saag MS
Top Antivir Med; 2019 Sep; 27(3):123-127. PubMed ID: 31634859
[TBL] [Abstract][Full Text] [Related]
52. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
53. Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.
Underwood M; Urbaityte R; Wang R; Horton J; Oyee J; Wynne B; Fox D; Jones B; Man C; Sievers J
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543770
[TBL] [Abstract][Full Text] [Related]
54. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
[TBL] [Abstract][Full Text] [Related]
55. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
[TBL] [Abstract][Full Text] [Related]
56. An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
M Llibre J; Raffi F; Moyle G; Behrens G; Bouee S; Reilly G; Borg P; Piontkowsky D; Rogatto F
PLoS One; 2016; 11(5):e0155406. PubMed ID: 27196332
[TBL] [Abstract][Full Text] [Related]
57. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice.
Baldin G; Ciccullo A; Lombardi F; D'Angelillo A; Dusina A; Emiliozzi A; Farinacci D; Moschese D; Picarelli C; Borghetti A; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):429-432. PubMed ID: 33280486
[TBL] [Abstract][Full Text] [Related]
58. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Rotea-Salvo S; Martínez-Pradeda A; Fernández-Oliveira C; Giménez-Arufe V; Balboa-Barreiro V; Margusino-Framiñán L; Mena-De-Cea Á; Vázquez-Rodríguez P; Castro-Iglesias Á; López-Calvo S; Martín-Herranz I; Míguez-Rey E; Cid-Silva P
Eur J Hosp Pharm; 2023 Jul; 30(4):221-226. PubMed ID: 34649965
[TBL] [Abstract][Full Text] [Related]
59. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV.
Christensen BL; Tan DH
Expert Opin Pharmacother; 2022 Mar; 23(4):439-446. PubMed ID: 35073817
[TBL] [Abstract][Full Text] [Related]
60. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
